Featured Technology
Alpha Cancer Technologies – the pharma company on a path to help cancer patients beat cancer and forget about toxic side effects of chemotherapy
The Canadian pharmaceutical company Alpha Cancer Technologies Inc. (ACT) is trying to change the current reality of chemotherapy and its side effects on suffering patients. The ACT team is utilizing recombinant human alpha-fetoprotein (AFP) conjugated cytotoxins to target cancer cells. The advantage of the approach employed by Alpha Cancer Technologies is that AFP binds to cells through specific receptors. These receptors are not present on normal cells in adults but they do show up on most tumor cells. Therefore, AFP will bind only to tumor cells. Alpha fetoprotein has the potential to be a class leading targeting agent because of its unique properties.
Featured Press Release
TriLink Enters into Distribution Agreement with Sigma-Aldrich
TriLink announced that it has entered into a distribution agreement with Sigma-Aldrich to sell its CleanAmp™ dNTPs globally.
Recent News
Dr. Richard Zhao, who is a Professor of Pathology, Microbiology-Immunology and Human Virology at the School of Medicine, University of Maryland Baltimore, discusses individualized molecular testing and personalized medicine in an interview with Alexander Kuklin, PhD at www.PersonalizedMedicineTV.com. He talks about Theragnostics, Prognomics, and Pharmacogenomics. (more)
Science Communicator and Rapper Oort Kuiper (the UK) discusses his song Genetics and his work as a song writer and performer at www.PersonalizedMedicineTV.com. (more)
bioteXcel consulting has recently been launched in the UK by it founder Elisabetta Fineschi. The company boasts a global footprint by having a team of professionals spanning China, India, Europe, US and Canada. This article discusses the beginning of bioteXcel and the visions of its founder. (more)
Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD2) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment. (more)
infoQuant Ltd brings microarray technology closer to clinical use with its latest release of copy number analysis and interpretation software oneClickCGH and CGH Fusion for microarray-based comparative genomic hybridization tests (array CGH). (more)
Biotech Market Summary
| symbol | last price | date | time | change | open | high | low | volume |
|---|---|---|---|---|---|---|---|---|
| AFFY | 7.23 | 1/27/2012 | 2:31pm | +0.08 | 7.13 | 7.3998 | 7.13 | 291132 |
| ILMN | 51.995 | 1/27/2012 | 2:32pm | -0.655 | 52.46 | 52.8788 | 51.94 | 3374977 |
| ARNA | 1.585 | 1/27/2012 | 2:32pm | +0.025 | 1.57 | 1.60 | 1.56 | 1211238 |
| VRUS | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| GENZ | 0.00 | N/A | 5:-230pm | N/A | N/A | N/A | N/A | N/A |
| A | 42.6958 | 1/27/2012 | 2:32pm | +0.0358 | 42.38 | 42.95 | 42.27 | 1863014 |
| MRK | 38.505 | 1/27/2012 | 2:32pm | -0.275 | 38.73 | 38.80 | 38.22 | 8072310 |